Chimerix Inc. Stock
Chimerix Inc. Stock
Pros and Cons of Chimerix Inc. in the next few years
Pros
Cons
Performance of Chimerix Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Chimerix Inc. | -2.110% | -8.691% | -14.215% | -21.899% | 3.884% | -87.426% | -62.251% |
| Ardelyx Inc. | -0.620% | -12.086% | -15.475% | 35.391% | 4.706% | -16.524% | - |
| Salarius Pharmaceuticals Inc. | 1.850% | 10.553% | -19.266% | -71.613% | -20.721% | -98.176% | -99.994% |
| Evolus Inc | -1.830% | -7.627% | -15.504% | 39.744% | 16.578% | 15.344% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon first glance, the financials of Chimerix, a biotechnology and medical research company with the US symbol CMRX, reveal both positive and negative indicators. Notably, the company has experienced significant variations in its cash position and net income throughout the reviewed years. These financials are typical for companies in the biotechnology and medical research industry, as they often spend heavily on research and development (R&D) while waiting for regulatory approvals and the launch of key products.
Growing Total Assets: Chimerix's total assets have increased over the years, from $84.72 million in 2020 to $279.34 million in 2022, and finally reaching $258.53 million in Q1 2023. This demonstrates the company's ability to accumulate assets and invest in its operations on a consistent basis.
Substantial Investments: The company has made significant investments throughout the years, with long-term investments increasing from $2.02 million in 2021 to $48.63 million in 2022 and standing at $31.32 million in Q1 2023. This indicates that Chimerix is putting its resources into potentially lucrative long-term projects or acquisitions.
Comments